Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
University Hospital, Antwerp
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07020715CT.gov A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis | — | Not Yet Recruiting | — | — | — |
NCT06715605CT.gov A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS | — | Withdrawn | — | — | — |
NCT02618902CT.gov A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial | — | Completed | — | — | — |
NCT02283671CT.gov Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tolerogenic Dendritic Cells (this asset) | University Hospital, Antwerp | P2 | CCC · 52 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Tolerogenic Dendritic Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuromyelitis Optica | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tolerogenic Dendritic Cells in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tolerogenic-dendritic-cells-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →